Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.

Frontage Holdings Announces 2020 Interim Results

Since March 2020, the number of COVID-19 cases continued to rise in the United States, which negatively affected the Group’s business. The global pandemic has limited the full capacity of the Group’s employees performing laboratory services and lowered its delivery efficiency. The Group has employed various mitigation measures focusing on the safety and well-being of its employees, customers and partners, and the continuity of its business operations to minimize the adverse impact of the pandemic. The Group’s facilities in the United States continue to operate at a reduced utilization rate.

Frontage announces the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc and President of Frontage Greater China.

Frontage is pleased to announce the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc. and President of Frontage Greater China. Dr. Qi has nearly 30 years of experience in research and development leadership and overseeing operations in the regulated pharmaceutical industry. In this role, Dr. Qi will be responsible for the overall leadership and strategic growth of Frontage Greater China operations.

Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.

Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.

ANVISA Certification

Brazil’s Agencia Nacional de Vigilancia Sanitaria (ANVISA) approved Frontage Laboratories to conduct bioanalytical services to support bioequivalence studies. ANVISA certified that Frontage Laboratories meets the agency’s stringent biopharmaceutical safety guidelines allowing the company to conduct bioanalytical work on its clients drug products.  The certification will be valid until August 2022. and has been published on ANVISA website (www.anvisa.gov.br.) 

Frontage expands synthetic & medicinal chemistry and process research & development services by acquisition of ACME Bioscience

ACME provides discovery chemistry, medicinal chemistry, process chemistry research & development, and chemical manufacturing services for worldwide biopharmaceutical companies.  ACME has extensive experience in antiviral and anti-bacterial research, along with expertise in nucleotides, nucleosides, triphosphates pro-drugs, heterocycles, and boron containing compounds, and has partnered with many customers in developing new chemical entities.

Frontage Laboratories, Inc establishes a QWBA Center of Excellence (COE) in Exton PA

Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services, has established a Quantitative Whole‑Body Autoradiography (QWBA) Center of Excellence (COE) at our Exton PA facility. 

Frontage develops a 3 in 1 multiplex PK assay for evaluation of hydroxy-chloroquine, chloroquine and azithromycin in human plasma to support COVID-19 clinical trials

In the battle against COVID-19, Frontage Bioanalytical, a contract research organization (“CRO”) providing integrated, science-driven, product development services, is first to announce development of potential cocktail PK assay for hydroxy-chloroquine, chloroquine and azithromycin in human plasma.

Frontage Announces the Appointment of Michael J. Potchoiba, M.S to Head the QWBA-Center of Excellence in Exton, PA.

Frontage Laboratories, Inc., is pleased to announce the appointment of Michael J. Potchoiba, M.S to head the QWBA-Center of Excellence in Exton, PA.

Frontage Laboratories, Inc. Response to COVID-19 (May 2020)

Dear Valued Clients and Partners:
I hope this email finds you and your families doing well and staying safe and healthy during these difficult times. At Frontage, despite some modifications to how we operate, our commitment to our clients remain as strong as ever.